Lilly Completes Acquisition Of Sigilon Therapeutics

Aug 14, 2023•almost 2 years ago

Acquiring Company

Eli Lilly and Company

Acquired Company

Sigilon

IndianapolisPharmaceuticalManufacturingHealth CareBiotechnologyHealth Care

Description

Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Sigilon Therapeutics, Inc. (NASDAQ: SGTX). The acquisition allows Lilly to continue researching and developing encapsulated cell therapies, including SIG-002, for the treatment of type 1 diabetes.

Company Information

Company

Eli Lilly and Company

Location

Indianapolis, Indiana, United States

About

Lilly is a medicine company turning science into healing to make life better for people around the world. They have been pioneering life-changing discoveries for nearly 150 years, and today their medicines help more than 51 million people across the globe. Lilly is focused on redefining diabetes care, treating obesity, advancing the fight against Alzheimer's disease, providing solutions to immune system disorders, and transforming difficult-to-treat cancers into manageable diseases.

M&A Insights

Based on deal data

Integration timeline

70% of M&A integrations take 12-24 months to complete

Tech stack consolidation

83% of merged companies consolidate technology vendors within first year

Post-acquisition investment

Companies increase IT spending by 23% on average after acquisitions

Success factor

M&A deals with strong technology integration plans are 2.5x more likely to succeed

Related People

Lilly Completes Acquisition Of Sigilon Therapeutics

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

M&A Insights

Related People

Lucas hidden

Gordon hidden

Melissa hidden

Company Information